A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape

Abstract Background Immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of many cancers. However, the limited population that benefits from ICI therapy makes it necessary to screen predictive biomarkers for stratifying patients. Currently, many biomarkers, such as tumor mutati...

Full description

Bibliographic Details
Main Authors: Junyu Long, Dongxu Wang, Anqiang Wang, Peipei Chen, Yu Lin, Jin Bian, Xu Yang, Mingjun Zheng, Haohai Zhang, Yongchang Zheng, Xinting Sang, Haitao Zhao
Format: Article
Language:English
Published: BMC 2022-02-01
Series:Genome Medicine
Subjects:
Tumor microenvironment
Biomarker
Immune response
Immune checkpoint inhibitor
Immunotherapy
Online Access:https://doi.org/10.1186/s13073-022-01024-y

Internet

https://doi.org/10.1186/s13073-022-01024-y

Similar Items